Humanization of an antibody directed against IgE.

IgE antibodies bind to specific high-affinity receptors on mast cells, leading to mast cell degranulation and release of mediators, such as histamine, which produce symptoms associated with allergy. Hence, anti-IgE antibodies that block binding of IgE to its high-affinity receptor are of potential therapeutic value in the treatment of allergy. These antibodies must also not bind to IgE once it is bound to the receptor because this would trigger histamine release. This study describes the humanization of a murine antibody, MaE11, with these characteristics. Variants of the humanized antibody were evaluated to probe the importance of framework residues on antibody binding and to determine which charged residues in the CDR interacted with IgE. We found that only five changes in human framework residues were required to provide for binding comparable to that of the original murine antibody.

• Publication year

  1993

• Venue

  Journal of Immunology

• Publication date

  1993-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4049/jimmunol.151.5.2623PMID 8360482
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling.

  1993cited by this paper
• High Level Escherichia coli Expression and Production of a Bivalent Humanized Antibody Fragment

  1992cited by this paper
• Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene

  1992cited by this paper
• Antigen binding thermodynamics and antiproliferative effects of chimeric and humanized anti-p185HER2 antibody Fab fragments.

  1992cited by this paper
• The receptor with high affinity for IgE.

  1992cited by this paper
• The Low‐Affinity Receptor for IgE

  1992cited by this paper
• Humanization of an anti-p185HER2 antibody for human cancer therapy.

  1992cited by this paper
• Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys.

  1991cited by this paper
• Reshaping a therapeutic CD4 antibody.

  1991cited by this paper
• A humanized monovalent CD3 antibody which can activate homologous complement

  1991cited by this paper
• Humanized antibodies for antiviral therapy.

  1991cited by this paper
• Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation.

  1991cited by this paper
• A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties.

  1991cited by this paper
• Construction, expression and characterization of humanized antibodies directed against the human alpha/beta T cell receptor.

  1991cited by this paper
• Reshaping a Human Monoclonal Antibody to Inhibit Human Respiratory Syncytial Virus Infection in Vivo

  1991cited by this paper
• The alpha subunit of the human IgE receptor (FcERI) is sufficient for high affinity IgE binding.

  1990cited by this paper
• Analysis of protein digests by capillary high-performance liquid chromatography and on-line fast atom bombardment mass spectrometry.

  1990cited by this paper
• Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders.

  1990cited by this paper
• Conformations of immunoglobulin hypervariable regions

  1989cited by this paper
• Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. II. Pharmacokinetics and immune response.

  1988cited by this paper
• Two species of human Fc epsilon receptor II (Fc epsilon RII/CD23): tissue-specific and IL-4-specific regulation of gene expression.

  1988cited by this paper
• Monoclonal antibody therapy. Anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression.

  1986cited by this paper
• Replacing the complementarity-determining regions in a human antibody with those from a mouse

  1986cited by this paper
• From parasites to allergy: a second receptor for IgE.

  1986cited by this paper
• Three-dimensional structure of an antigen-antibody complex at 2.8 A resolution

  1986cited by this paper
• The receptor with high affinity for immunoglobulin E.

  1986cited by this paper
• Human immune response to multiple injections of murine monoclonal IgG.

  1985cited by this paper
• Rapid and efficient site-specific mutagenesis without phenotypic selection.

  1985cited by this paper
• A novel procedure for labeling immunoglobulins by conjugation to oligosaccharide moieties.

  1984cited by this paper
• Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma.

  1984cited by this paper
• High efficiency DNA-mediated transformation of primate cells.

  1983cited by this paper
• Biochemical analysis of initial triggering events of IgE-mediated histamine release from human lung mast cells.

  1983cited by this paper
• Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma.

  1983cited by this paper
• Characteristics of a human cell line transformed by DNA from human adenovirus type 5.

  1977cited by this paper
• Binding of IgE myeloma proteins to human cultured lymphoblastoid cells.

  1976cited by this paper
• Conjugation of antibodies with fluorochromes: modifications to the standard methods.

  1976cited by this paper
• Biologic function of the Fc fragments of E myeloma protein.

  1970cited by this paper
• DNA Restriction Enzyme from E. coli

  1968cited by this paper

• Emerging diagnostic and therapeutic opportunities in food allergy

  2026cites this paper
• Omalizumab is ineffective in regulating proasthmatic serum cytokine and chemokine levels in nonresponders with high BMI

  2025cites this paper
• Efficacy of Omalizumab against Japanese Cedar pollinosis in clinical practice

  2025cites this paper
• Novel biomarkers in asthma

  2025cites this paper
• Short‐Term Efficacy of Biologics in Recalcitrant Allergic Fungal Rhinosinusitis: A Systematic Review and Meta‐analysis

  2025cites this paper
• Omalizumab controls surface phenotypes of dendritic cells and monocytes in asthma

  2025cites this paper
• Neutralizing serum IgE upregulates CD88 and CRTH2 expression on basophils in patients with asthma

  2025cites this paper
• Autoallergy and what the Allergist Needs to know

  2025cites this paper
• Diagnostik und medikamentöse Therapie der chronischen Rhinosinusitis

  2025cites this paper
• Monitoring lysosomal catabolism: a sensitive probe for assessing targeted lysosomal degradation of extracellular proteins

  2024cites this paper
• Omalizumab Safety Concerns.

  2024cites this paper
• Frequency of Severe Asthma and Its Clinical Phenotypes at the Asthma Clinic in One of the Largest Sudanese Tertiary Pediatric Hospitals: A Cross-Sectional Hospital-Outpatient-Based Study

  2024influential citation
• Critical pathomechanisms of NSAID-exacerbated respiratory disease (N-ERD) clarified by treatment with omalizumab, an anti-IgE antibody.

  2024cites this paper
• Allosteric inhibition of IgE–FcεRI interactions by simultaneous targeting of IgE F(ab’)2 epitopes

  2024cites this paper
• Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways

  2024cites this paper
• Modulation of the high concentration viscosity of IgG1 antibodies using clinically validated Fc mutations

  2024cites this paper
• Generation of a virus‐like particles based vaccine against IgE

  2024cites this paper
• Therapies for Chronic Spontaneous Urticaria: Present and Future Developments

  2024cites this paper
• Biologics for severe asthma and beyond.

  2023cites this paper
• Self-reactive IgE and anti-IgE therapy in autoimmune diseases

  2023cites this paper
• Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status

  2023cites this paper
• Therapeutic Antibodies in Medicine

  2023cites this paper
• Autoreactive IgE: Pathogenic role and therapeutic target in autoimmune diseases

  2023cites this paper
• Therapeutic tactics for targeting B lymphocytes in autoimmunity and cancer

  2023cites this paper
• Efficacy and safety of monoclonal antibody therapy for chronic rhinosinusitis with nasal polyposis

  2022cites this paper
• Therapeutical Targets in Allergic Inflammation

  2022cites this paper
• A perspective toward mass spectrometry-based de novo sequencing of endogenous antibodies

  2022cites this paper
• Oral administration of Helianthus annuus leaf extract ameliorates atopic dermatitis by modulation of T cell activity in vivo.

  2022cites this paper
• Local Immunoglobulin E in nasal polyps: Role and modulation

  2022cites this paper
• Characterization and pre-clinical assessment of a proposed biosimilar to its originator Omalizumab.

  2022cites this paper
• The efficacy of omalizumab treatment in patients with non-atopic severe asthma

  2022cites this paper
• Regulatory T cells and immunoglobulin E: A new therapeutic link for autoimmunity?

  2022cites this paper
• Omalizumab for the treatment of allergic rhinitis: a systematic review and meta-analysis.

  2021cites this paper
• Biologics in Treatment for Chronic Rhinosinusitis with Comorbid Asthma

  2021cites this paper
• Anti-IgE: A treatment option in allergic rhinitis?

  2021cites this paper
• Combining Anti-IgE Monoclonal Antibodies and Oral Immunotherapy for the Treatment of Food Allergy

  2021cites this paper
• IgE in the pathophysiology and therapy of food allergy

  2021cites this paper
• Impact of omalizumab on pollen‐induced seasonal allergic rhinitis: An observational study in clinical practice

  2021cites this paper
• CHOK1SV GS‐KO SSI expression system: A combination of the Fer1L4 locus and glutamine synthetase selection

  2021cites this paper
• Positionspapier: Hinweise zur Patienteninformation und -aufklärung vor Anwendung von Biologika bei chronischer Rhinosinusitis mit Nasenpolypen (CRSwNP) – Teil 2: Omalizumab – Empfehlungen des Ärzteverbandes Deutscher Allergologen (AeDA) und der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Hal

  2021cites this paper
• Additional Biologic Therapeutics

  2021cites this paper
• Effectiveness and Safety Studies of Omalizumab in Children and Adolescents With Moderate-To-Severe Asthma

  2021cites this paper
• Emerging concepts and directed therapeutics for the management of asthma: regulating the regulators

  2020cites this paper
• Targeted Molecular Therapies in Allergy and Rhinology

  2020cites this paper
• The Importance of IgE and the Uses of Anti-IgE

  2020cites this paper
• Effects of Omalizumab Treatment in Patients With Recalcitrant Nasal Polyposis and Mild Asthma: A Multicenter Retrospective Study

  2020cites this paper
• When Should We Use Biologics in Rhinology?

  2020cites this paper
• Omalizumab-induced colitis.

  2020cites this paper
• Determinants of omalizumab dose-related efficacy in oral immunotherapy: evidence from a cohort of 181 patients.

  2020cites this paper
• Biologics in the Treatment of Asthma.

  2020cites this paper
• Effectiveness and Safety of Omalizumab in Patients with Allergic Bronchopulmonary Aspergillosis Complicated by Chronic Bacterial Infection in the Airways

  2020cites this paper
• Add-on omalizumab for inadequately controlled severe pollinosis despite standard-of-care: a randomized study.

  2020cites this paper
• Novel TLR2xTLR4 Bispecific Antibody Inhibits Bacterial Sepsis

  2020cites this paper
• Past, present, and future of anti‐IgE biologics

  2020cites this paper
• Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapy

  2020cites this paper
• Whole blood transcriptional variations between responders and non‐responders in asthma patients receiving omalizumab

  2020cites this paper
• Chronic Rhinosinusitis with Nasal Polyps: Targeting IgE with Anti-IgE Omalizumab Therapy

  2020cites this paper
• Adrenal insufficiency is a contraindication for omalizumab therapy in mast cell activation disease: risk for serum sickness

  2020cites this paper
• The Role of Biologics and Precision-Based Medicine in Treating Atopic Diseases in Children

  2020cites this paper
• Switching between biologics in severe asthma patients. When the first choice is not proven to be the best

  2020cites this paper
• SARS-CoV-2 in a Patient with Persistent Asthma Taking Omalizumab: The First Case in Turkey

  2020cites this paper
• Computationally grafting an IgE epitope onto a scaffold: Implications for a pan anti-allergy vaccine design

  2020cites this paper
• Structure of intact IgE and the mechanism of ligelizumab revealed by electron microscopy

  2020cites this paper
• European Position Paper on Rhinosinusitis and Nasal Polyps 2020.

  2020cites this paper
• Biologics in the Treatment of Asthma

  2020cites this paper
• Therapeutic Monoclonal Antibodies: Structure, Nomenclature and Current Approved Product Review

  2019cites this paper
• Antibody Structure and Function: The Basis for Engineering Therapeutics

  2019cites this paper
• The anti-IgE mAb Omalizumab induces adverse reactions by engaging Fcγ receptors.

  2019cites this paper
• Место омализумаба в терапии аллергических заболеваний

  2019cites this paper
• Childhood atopic dermatitis: current developments, treatment approaches, and future expectations

  2019cites this paper
• Anti-IgE treatment in allergic rhinitis.

  2019cites this paper
• Immunotherapy and biologicals for the treatment of allergy to Hymenoptera stings

  2019cites this paper
• A call for cost-effectiveness analysis for biologic therapies in chronic rhinosinusitis with nasal polyps.

  2019cites this paper
• The place of Omalizumab in the treatment of allergic diseases

  2019cites this paper
• Immune repertoire mining for rapid affinity optimization of mouse monoclonal antibodies

  2019cites this paper
• Production of Humanized Antibody against Human Hig in a Serum-free Culture of CHO Cells , and Purificationh-aMnity IgE Receptor of the Fab Fragments

  2018cites this paper
• Trapping IgE in a closed conformation by mimicking CD23 binding prevents and disrupts FcεRI interaction

  2018cites this paper
• Approaches to target IgE antibodies in allergic diseases.

  2018cites this paper
• Novel therapies for severe asthma in children and adults

  2018cites this paper
• The use of omalizumab in allergen immunotherapy

  2018cites this paper
• Severe Bronchial Asthma in the era of biological treatments

  2018cites this paper
• Construction of humanized anti-HER2 single-chain variable fragments (husFvs) and achievement of potent tumor suppression with the reconstituted husFv-Fdt-tBid immunoapoptotin.

  2018cites this paper
• Two decades with omalizumab: what we still have to learn

  2018cites this paper
• Chronic spontaneous urticaria treated with omalizumab: report of two cases

  2018cites this paper
• The effect of omalizumab treatment on IgE and other immunoglobulin levels in patients with chronic spontaneous urticaria and its association with treatment response

  2018cites this paper
• Efficacy, safety and cost effectiveness of oral doxofylline and theophylline for mild to moderate persistent bronchial asthma: A randomized prospective open labeled comparative study

  2018cites this paper
• Omalizumab for Severe Asthma: Beyond Allergic Asthma

  2018cites this paper
• Periostin and Dipeptidyl Peptidase-4: Potential Biomarkers of Interleukin 13 Pathway Activation in Asthma and Allergy.

  2018cites this paper
• Anti-IgE therapy for IgE-mediated allergic diseases: from neutralizing IgE antibodies to eliminating IgE+ B cells

  2018cites this paper
• The Fab fragment of anti-IgE Cε2 domain prevents allergic reactions through interacting with IgE-FcεRIα complex on rat mast cells

  2018cites this paper
• Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness

  2018cites this paper
• Anti-IgE therapy for asthma: an audit at a tertiary care centre in Saudi Arabia

  2018cites this paper
• Biologics for the Treatment of Atopic Dermatitis

  2018cites this paper
• Efficacy and safety of Omalizumab in the treatment of Chronic Urticarial; a case series.

  2018cites this paper
• Are Biologics Efficacious in Atopic Dermatitis? A Systematic Review and Meta-Analysis

  2018cites this paper
• Biologics in chronic urticaria.

  2017cites this paper
• Utilizing Solid Phase Cloning , Surface Display And Epitope Information for Antibody Generation and Characterization

  2017cites this paper
• Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety

  2017cites this paper
• A review of the new treatment of allergic asthma and seasonal allergic rhinitis

  2017cites this paper
• Anti-IgE Therapy

  2017cites this paper